Arrowhead’s blood-brain barrier tech is ‘arguably better’ than others, analysts say after data drop

Arrowhead Pharmaceuticals’ siRNA candidate achieved “compelling” tau reductions in an early study of healthy volunteers, with a magnitude of effect that seems to outperformother blood-brain barrier platforms, according to Stifel.